Pharma BD Deal Intelligence
Sumitomo Dainippon Pharma acquired Roivant's interests in five 'Vant' subsidiaries — Myovant, Urovant, Enzyvant, Altavant and Spirovant — bundled under a new holding company, Sumitovant Biopharma, plus an equity stake in Roivant itself. Per Sumitomo's completion disclosure, total consideration was approximately US$3 billion (~JPY 330 billion): US$2.0 billion for 100% of Sumitovant Biopharma (the five Vants) and US$1.0 billion for an 11% equity stake in Roivant. The deal also granted Sumitomo options over six additional Roivant biopharma companies and access to Roivant's DrugOme and Digital Innovation technology platforms. Announced October 31, 2019; closed December 27, 2019, with Sumitovant launched as a wholly owned subsidiary led by CEO Myrtle Potter. Sumitomo subsequently consolidated the portfolio: Urovant was taken private (announced November 2020); Sumitovant completed the buy-in of the remaining Myovant shares it did not own on March 10, 2023 (~US$1.7 billion, NYSE delisting); and the U.S. entities were combined into Sumitomo Pharma America effective July 1, 2023.
Assessment window: 5yr post-close.